Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Package Catalog No. Price(In USD) Qty (Quantity) Sum(In USD)
1mg GMP-V-2019nCoV-Smu-002-1mg 5990
10mg GMP-V-2019nCoV-Smu-002-10mg 38790
100mg GMP-V-2019nCoV-Smu-002-100mg 258000
≥100mg GMP-V-2019nCoV-Smu-002-xmg Inquiry
Shipping Cost: 760.00
Total:



Description

Accession Number QHD43415.1
Expression platform 2019-nCoV(SARS-CoV-2, SARS2-coronavirus)
IsotypesMamamlian (human cell)
TagC-His
Products descriptionRecombinant 2019-nCoV(SARS-CoV-2)-UK variant B.1.1.7 lineage receptor binding domain (RBD) from the Spike Protein (S protein) with N501Y mutation was expressed in mammanlian cell (human cells) expression system with 6 HIS tag at the C-terminus.
Bioactivity validation ACE2 binding;
Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
PurityPurity: ≥95% (SDS-PAGE)
ApplicationSpike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies.
Immunogen in Elisa,lateral-flow tests,and other immunoassays;
Standard substance
The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
predicted Molecular Mass35kDa
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus) antigen:
Recombinant 2019-nCoV(SARS-CoV-2) (UK variant B.1.1.7 lineage) Spike Protein RBD-N501Y mutant (SRBD-N501Y,C-HisTag)

Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19vaccines and therapeutic antibodies.



Products & Information Collection of SARS-CoV-2 (2019nCOV)spike-N501Y mutation

The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. Most mutations and deletions of SARS-CoV-2 occur in the coronavirus spike protein. Spike position N501, one of the key contact residues in the receptor-binding domain (RBD), and experimental data suggest mutation N501Y can increase ACE2 receptor affinity (Starr et al. 2020). N501Y has also been associated with increased infectivity and virulence in a mouse model (Gu et al. 2020).

Recently a novel SARS-COV-2 (2019nCOV) lineage, the B.1.1.7 lineage, with serials of site mutation, shows stronger infection ability in the UK. In SARS-COV-2 B.1.1.7 lineage, most mutations and deletions occur in the coronavirus spike protein. These mutantions also include SARS-CoV-2 spike- mutation. N501Y mutation is also found in the South Africa 501Y.V2 lineage(B.1.351).

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation

Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-N501Y mutation, which will meet the evaluation of the efficacy of COVID-19 vaccines and therapeutic antibodies.

Cat No. Antigen Name of 2019-nCoV(SARS-CoV-2) Isotypes Order
GMP-V-2019nCoV-Smu-002Recombinant 2019-nCoV(SARS-CoV-2) (UK variant B.1.1.7 lineage)
Spike Protein RBD-N501Y mutant (SRBD-N501Y, C-HisTag)
Mammalian (human cell)Picture loading failed.
GMP-H-ACE2001Recombinant human solubale ACE2 protein
(soluble hACE2,extracellular hACE2, C-His)
Mammalian (human cell)Picture loading failed.
GMP-H-ACE2002Recombinant human solubale ACE2 protein
(soluble hACE2,extracellular hACE2, C-His)
Mammalian (human cell)Picture loading failed.

SARS-COV-2 (2019nCOV) variant-N501Y mutation of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) spike-N501Y mutation

GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) spike-N501Y mutation

Reference:
1 Gu, Hongjing, Qi Chen, Guan Yang, Lei He, Hang Fan, Yong-Qiang Deng, Yanxiao Wang, et al. 2020. “Adaptation of SARS-CoV-2 in BALB/c Mice for Testing Vaccine Efficacy.” Science 369 (6511): 1603–7.
2 Starr, Tyler N., Allison J. Greaney, Sarah K. Hilton, Daniel Ellis, Katharine H. D. Crawford, Adam S. Dingens, Mary Jane Navarro, et al. 2020. “Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.” Cell 182 (5): 1295–1310.e20.